Meanwhile, the newest CDK4/CDK6 inhibitor, trilaciclib, is being studied in small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC) in a bid to prevent chemotherapy-induced myelosuppression [20,21]. The gene discussed is CDK6; the disease is small cell lung carcinoma.